慢性腎臓病および糖尿病における腎機能/アルブミン尿によるフィネレノンおよび心不全のアウトカム From @jaccjournals https://t.co/VbAg8wewPH
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
RT @Darbepoeti_n: MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわか…
MR阻害薬である「フィネレノン」はDMを合併するCKD患者で有効であることが報告されています。この研究によると、腎機能が保たれ(eGFR>60)・アルブミン尿レベルの(UACR<300)の患者で、 ✓心不全発症を最も抑制できる ことがわかった。早期の介入が重要と言えそうです。 https://t.co/LV0PvaSExq https://t.co/AklBdpIT32
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @chemachir: Arma terapéutica que estamos deseando poder usar en nuestros pacientes con enfermedad renal y diabetes …@IcyfaSemi @Diabetes…
RT @chemachir: Arma terapéutica que estamos deseando poder usar en nuestros pacientes con enfermedad renal y diabetes …@IcyfaSemi @Diabetes…
RT @KerendiaEsp: In the FIDELITY (FIDELITY-HF) study, #finerenone compared with placebo, improves heart failure-related outcomes in patient…
RT @KerendiaEsp: In the FIDELITY (FIDELITY-HF) study, #finerenone compared with placebo, improves heart failure-related outcomes in patient…
RT @KerendiaEsp: In the FIDELITY (FIDELITY-HF) study, #finerenone compared with placebo, improves heart failure-related outcomes in patient…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
In the FIDELITY (FIDELITY-HF) study, #finerenone compared with placebo, improves heart failure-related outcomes in patients with CKD and DM2. The beneficial effects of finerenone were independent of baseline eGFR and/or UACR. https://t.co/82IL7KHuNG http
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @Manugrillo2: #Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria i... https://t.co/lNHoDlDm3K
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @chemachir: Arma terapéutica que estamos deseando poder usar en nuestros pacientes con enfermedad renal y diabetes …@IcyfaSemi @Diabetes…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
Arma terapéutica que estamos deseando poder usar en nuestros pacientes con enfermedad renal y diabetes …@IcyfaSemi @Diabetes_SEMI @fjcarrascos @CarreteroJuani @pedropabloce @FormigaFrancesc @jopesilver @paullaceriborra @JesusCasado20 @MartaCoboMarcos @jrub
最近ではFinerenoneのエビデンスとかもあると認識していたけど。尿中アルブミン<300mgで介入の方がアウトカム良さそう。DM性腎症では定期的に測っています。 https://t.co/yChshoJi83
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
#Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria i... https://t.co/lNHoDlDm3K
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
RT @jlgorriz: In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients wi…
In the FIDELITY (FIDELITY-HF) study, finerenone compared with placebo, improves heart failure-related outcomes in patients with CKD and DM2. The beneficial effects of finerenone were independent of baseline eGFR and/or UACR. 🆓➡️ https://t.co/RS8VcMWgaE @s
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
A wonderful overview of spironolactone and eplerenone for #HFrEF. Looking forward to HFmrEF/pEF outcomes of #Finerenone in FINEARTS-HF (and hopefully one day in HFrEF!). HF analysis in @JACCJournals (from FIDELIO-DKD & FIGARO-DKD) already very promisi
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @AndrewJSauer: Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes | JACC: Heart…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @AndrewJSauer: Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes | JACC: Heart…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @AndrewJSauer: Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes | JACC: Heart…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes | JACC: Heart Failure https://t.co/hRWENAwnsv
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
More evidence of MRAs @AndrewJSauer will be happy
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
And together with Jeff Testani we put these findings in perspective: https://t.co/ZVeBwAL8Dj
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
RT @md_viviana: More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finereno…
More evidence to support the use of MRAs in heart Failure patients, in this @JACCJournals HF by @Filippatos et al. Finerenone improved HF related outcomes across CKD stages, more evidence needed in pts with GFRs of < than 25 (ml/min/1.73 m2) https://t.c
#Finerenone improved HF-related outcomes in patients with CKD and T2D, with consistent benefits across eGFR and/or UACR categories. (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease From @jaccjournals
Finerenona mejora la insuficiencia cardíaca en pacientes con nefropatía crónica y diabetes tipo 2, dependiendo de la filtración glomerular y de la albuminuria #CKG #T2D #eGFR #UACR #finererone https://t.co/fcPhjabW0i
RT @KerendiaEsp: #Finerenone and #HeartFailure Outcomes by Kidney Function/Albuminuria in #CKD and DM This subgroup analyses by baseline #…
RT @Manugrillo2: #finerenone improved HF-related outcomes in patients with CKD and T2D, with consistent benefits across eGFR and/or UACR ca…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…
RT @BiykemB: UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD…